JADE3 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with disruption of the human JADE3 gene. Established on the HT29 colorectal adenocarcinoma line, these cells provide a loss-of-function model to study JADE3 biology. This polyclonal product reflects a heterogeneous editing pool, ideal for population-based functional assays without clonal artifacts.
HT29 is an epithelial cell line derived from a primary colon tumor of a 44-year-old female. Widely used for intestinal differentiation and colorectal cancer research, HT29 cells harbor mutations in APC, TP53, and KRAS, representing a clinically relevant model. They can differentiate into enterocyte-like cells under appropriate conditions, enabling studies on epigenetic regulation within a cancer context and providing a physiologically relevant system for colorectal tumorigenesis research.
JADE3 is a scaffold protein in the HBO1 (KAT7) acetyltransferase complex, which also includes ING4/ING5, MEAF6, and BRPF1/2/3. This complex catalyzes histone H4 acetylation at lysines 5, 8, and 12, a modification that relaxes chromatin structure. JADE3 functions downstream of the MYC transcription factor to promote transcriptional activation of proliferation-associated genes and facilitate DNA replication licensing by enabling MCM helicase loading at origins through local H4 acetylation. Its interactions with HBO1 and ING proteins are essential for substrate targeting and full acetyltransferase activity.
In HT29 cells, JADE3??s role in chromatin dynamics is particularly relevant to colorectal cancer epigenetics and uncontrolled proliferation. Disrupting JADE3 allows researchers to dissect how HBO1-mediated histone H4 acetylation influences MYC-driven transcriptional programs, cell cycle progression, and replication origin firing within a tumorigenic background. This model thus provides a platform to investigate the contribution of JADE3-dependent epigenetic mechanisms to oncogenic processes in colon cancer.
These knockout cells are suited for a range of assays, including western blotting for acetylated histone H4, RT-qPCR for MYC target gene expression, RNA-seq for transcriptomic profiling, ChIP-qPCR for H4K5ac at replication origins, flow cytometry for cell cycle distribution, BrdU incorporation for proliferation measurement, DNA fiber assays for replication dynamics, and colony formation for tumorigenic potential. Applications encompass the study of HBO1 complex function, epigenetic control of proliferation, DNA replication licensing mechanisms, and validation of therapeutic targets in colorectal cancer. For further information, please contact Ascent Research.
